La chaîne d'options affiche les données clés des options sur actions de TransCode Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour TransCode Therapeutics..

TransCode Therapeutics (NASDAQ:RNAZ) Stock, Chaîne d'Options

TransCode Therapeutics

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) has outperformed the market over the past 15 years by 10.2% on an annualized basis producing an average annual return of 21.55%. Currently, Shopify has a market capitalization of $124.63 billion. 
Buying $1000 In SHOP: If an investor had bought $1000 of SHOP stock 15 years ago, it would be worth $18,998.58 today based on a price of $96.25 for SHOP at the time of writing.
<h3>Shopify's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746142212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

SHOP

Here's How Much $1000 Invested In Shopify 15 Years Ago Would Be Worth Today

Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) has outperformed the market over the past 20 years by 1.25% on an annualized basis producing an average annual return of 9.4%. Currently, Elevance Health has a market capitalization of $92.25 billion. 
Buying $1000 In ELV: If an investor had bought $1000 of ELV stock 20 years ago, it would be worth $6,004.56 today based on a price of $408.31 for ELV at the time of writing.
<h3>Elevance Health's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746141315_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Here's How Much $1000 Invested In Elevance Health 20 Years Ago Would Be Worth Today

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has <a href="https://www.benzinga.com/markets/25/04/45124373/tesla-board-explored-replacing-elon-musk-as-tesla-ceo-a-month-ago-report">shut down a report </a>that the company was actively looking to replace CEO Elon Musk.
While it remains to be seen if the report was factual or not, prediction markets saw odds that Musk leaves the company in 2025 spike.
What Happened: Facing<a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track"> weaker financials </a>and seeing CEO Musk spend more time with the White House working for the Department of Government Efficiency, Tesla's board of directors began searching for a new CEO about a month ago, according to a Wall Street Journal report.
The board reportedly told Musk he needed to devote more time to Tesla.
Following the release of the report, Tesla and Musk both denied that a search ever took place.
"It is an extremely bad breach of ethics that the @WSJ would publish a deliberately false article and fail to include an unequivocal denial beforehand by the Tesla board of directors!" Musk <a href="https://x.com/elonmusk/status/1917815854647107990">tweeted</a> while sharing the denial from Tesla's X account.
On prediction market Kalshi, the odds that Musk would be out as Tesla CEO in 2025 spiked to 19%. At the time of writing, the odds now stand at 16%. A high of 30% for the prediction market was hit back in June 2024 at 30%.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/TESLACEOCHANGE-25/markets/TESLACEOCHANGE-25?color_scheme=light&#038;widget_size=medium&#038;variant=a" width="488px" height="242px" style="border:0"></iframe>
Kalshi also offers a prediction <a href="https://kalshi.com/markets/kxteslaceochange/new-tesla-ceo#teslaceochange-26">market </a>on whether Musk will leave Tesla before 2027. This market has much higher chance at 35%, a figure up six points from yesterday.
Kalshi has many other Tesla- and Musk-related prediction markets open, including when Musk will leave DOGE, if Musk will remain the wealthiest person in 2025, when Musk will become a trillionaire, and if Musk will buy a major sports team.
On prediction market Polymarket, the <a href="https://polymarket.com/event/musk-out-as-tesla-ceo-in-2025">market </a>for Musk to be out as Tesla CEO in 2025 spiked to 19% last night and now sits at 15%.
Polymarket also has a <a href="https://polymarket.com/event/who-will-replace-musk-as-tesla-ceo?tid=1746107020420">market </a>for who will replace Musk as CEO of Tesla. The number one answer is no CEO announced. Following that option are two candidates who have more than 1%.
JB Straubel is listed with odds of 3% as the favorite. Straubel is the former chief technology officer of Tesla who spent 15 years with the company. Straubel is sometimes credited with a co-founder role for the company, given his early commitment to Tesla's development.
Omead Afshar is listed with odds of 2%. Afshar currently works at Tesla and is considered a close Musk ally and vice president of the electric vehicle company.
Listed beyond those two favorites are many candidates at odds of 1% that include the likes of Waymo CEO Tekedra Mawakana, General Motors CEO Mary Barra, Advanced Micro Devices CEO Lisa Su, Ford Motor Co. CEO Jim Farley, Uber CEO Dara Khosrowshahi and SpaceX CEO Gwynne Shotwell.
Another polarizing figure at 1% odds is Zach Kirkhorn, who worked at Tesla from 2010 to 2023. Kirkhorn served as Tesla's chief financial officer from 2019 to 2023.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: Tesla's brand may have been damaged by Musk and his push into politics. However, when people think of Tesla, they think of Musk.
Musk is also a key shareholder of Tesla. Without Musk's approval, it seems rather unlikely that he would leave as CEO.
The self-proclaimed wearer of many hats serves in leadership roles at several companies including Tesla, SpaceX and X, which does limit his full-time commitment to any company. With his role at the Department of Government Efficiency, Musk was less involved with Tesla.
Musk recently promised that he <a href="https://www.benzinga.com/news/management/25/05/45140155/musk-shifts-focus-back-to-tesla-says-doge-will-endure-without-him-is-buddha-needed-for-buddhism">would spend less time </a>at DOGE beginning May and spend more time at Tesla.
With new models coming, robotaxis and the Optimus Bot, Musk has expressed his optimism for Tesla and it's unlikely he would leave now.
Someday, Musk will leave Tesla or at least scale back his role. That is a day that Tesla shareholders and fans are likely not prepared for.
TSLA Price Action: Tesla stock closed Thursday at $280.52 versus a 52-week trading range of $157.40 to $488.54. Tesla stock is down 25.5% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/04/45108729/tesla-chairwoman-files-to-sell-more-stock-continuing-pattern-of-insider-sales-at-ev-giant">Tesla Chairwoman Files To Sell More Stock Continuing Pattern Of Insider Sales At EV Giant</a></li>
</ul>

Management

TSLA

Elon Musk Out As Tesla CEO In 2025? Prediction Markets Put Little Faith In WSJ Report, Here Are The Top Replacement Picks

Nobody likes talking about wills. It's right up there with colonoscopies and root canals — necessary, but not exactly dinner conversation. Still, financial guru Dave Ramsey isn't letting anyone off the hook. In a clip <a href="https://www.facebook.com/share/r/1EA4GkSnWK/?mibextid=wwXIfr">posted to his Facebook page</a>, Ramsey made it pretty clear: if you're going to ruffle feathers with your will, do it while you're alive — and do it loudly.
"If you're going to piss somebody off in the will, go ahead and do it while you're alive," Ramsey said. "Have a backbone. Instead of sneaking off into the grave and letting somebody else deal with their hurt feelings."
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
The post itself was just as direct, urging people to "Get your will done, and <a href="https://www.benzinga.com/personal-finance/25/04/44648769/32-year-old-tells-dave-ramsey-he-feels-guilty-after-being-only-one-to-inherit-grandmas-home-and-300k-no-one-deserved-anything-from-her">tell everybody what the stinking will says</a> while you're still alive."&nbsp;
He called out the drama people create when they treat their estate plans like a "deep, dark secret" — comparing it to a bad movie plot. "This is not a movie, it's your life," he snapped. And if you're a "crotchety old whatever" who wants to leave it all to your niece because your kids never call? Go ahead and tell them that, he said — and "shut up" about it.
The comment section, naturally, exploded — because nothing stirs emotions like money and family.
One person chimed in, saying, "I've been straight up with my kids all along. I told them they already received their inheritance in the form of private school, club sports and activities, and college tuition. They shouldn't be expecting anything when I pass." They added that the ball's now in their kids' court — they've been taught how to manage money and invest, and the rest is up to them.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Another user joked, "If you just make sure to spend every dime you make and live a life in debt you will never have to worry about estate planning lol." Certainly not the strategy Ramsey would recommend, but it's one way to avoid family squabbles.
<a href="https://www.ramseysolutions.com/retirement/estate-planning-guide">According to Ramsey Solutions</a>, estate planning isn't just about deciding who gets Grandma's china set. It's about protecting your entire life's work — your money, your kids, your pets — and making sure you, not a court, get the final say. It's <a href="https://www.benzinga.com/personal-finance/25/01/43278283/36-year-old-inherits-3-5-million-and-asks-dave-ramsey-the-best-way-to-invest-it-i-buy-real-estate-and-i-buy-mutual-funds-thats-all">more than just writing a will</a>. It's about setting up powers of attorney, trusts, and guardianship plans too.
And if you don't leave a plan? Well, the state's got one for you. Without a will, your estate is considered "intestate," and the court steps in to divide your assets based on your state's laws — usually following a strict order of succession.&nbsp;
That could mean your money and belongings end up with relatives you barely know or wouldn't have chosen. <a href="https://www.benzinga.com/personal-finance/24/12/42746966/debt-and-broke-are-the-norm-says-dave-ramsey-explains-why-normal-isnt-working-for-most-americans-and-how-to-take-control-of-your-money">Debts also come into play</a>, since creditors get first dibs on whatever you leave behind. Intestacy laws apply in all states, though the exact rules vary depending on where you live.
If you don't want your family starring in their own drama series after you're gone, take Ramsey's advice: have the talk now. No sneaking off into the grave.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

Dave Ramsey Urges 'Have a Backbone' — Tell People What's In Your Will While Alive Instead Of 'Sneaking Off Into The Grave' And Causing Drama

Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) has outperformed the market over the past 5 years by 7.83% on an annualized basis producing an average annual return of 22.13%. Currently, Axis Capital Holdings has a market capitalization of $7.87 billion. 
Buying $100 In AXS: If an investor had bought $100 of AXS stock 5 years ago, it would be worth $275.12 today based on a price of $97.42 for AXS at the time of writing.
<h3>Axis Capital Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746140418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Axis Capital Holdings Stock In The Last 5 Years

In 2012, <a href="https://www.benzinga.com/startups/25/01/43101102/elon-musk-the-richest-man-in-the-world-is-estimated-to-earn-over-23-million-every-single-hour-of-the-day-heres-how-hes-spending-it">Elon Musk</a> had a lot to say about bad car designs — and he didn't hold back.
During an <a href="https://youtu.be/L-s_3b5fRd8?si=wJX2ULtyzgA2zSGA">interview with tech entrepreneur and investor Kevin Rose</a>, Musk was asked why so many automakers seemed to "suck" — especially when it came to their design choices.
"I don't know. It blows my mind," he said. "It just seems like you can take a body panel and you can stamp it with that shape or this shape, and yet they choose to do the bad shape. But it costs the same either way."
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
He even went further, explaining: "You can make an ugly expensive car, you can make a good-looking expensive car, and actually the cost differences are relatively small."
Of course, "ugly" is in the eye of the beholder — one person's sleek modern design is another's design disaster. Still, Musk was clearly frustrated that automakers were spending luxury-level money and still delivering cars he thought looked bad.
At the time, Musk touted Tesla's approach: weekly design sessions where every curve and corner was obsessed over, filtered through engineering, safety, and regulations. It was a fresh take that helped Tesla's early models stand out in a sea of snooze-worthy sedans.
But fast forward to the present, and the internet is asking a different question: What happened to that guy?
Because these days, it's Musk's own Cybertruck that's getting roasted for looking… well, pretty ugly — and at a very expensive price.
Trending: Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.
<a href="https://www.benzinga.com/news/25/03/44536773/demand-is-off-the-charts-elon-musk-claimed-tesla-had-over-1-million-cybertruck-reservations-just-46096-have-been-sold-in-14-months">When the Cybertruck first debuted</a>, its sharp-angled, stainless steel body split opinions. Seeing it in person didn't help much. As one Tesla owner bluntly <a href="https://teslamotorsclub.com/tmc/threads/i-am-frankly-shocked-by-how-stunningly-ugly-the-cybertruck-is.326810/">put it in a forum post</a> last May, "I am frankly shocked by how stunningly ugly the Cybertruck is. Seeing it in person on the road is even more retina-burning than seeing it in pictures."
Critics didn't stop there. A <a href="https://www.cnn.com/2024/02/23/business/tesla-cybertruck-is-a-troubled-beast/index.html">CNN review</a> compared it unfavorably to the Ford F-150 Lightning, pointing out all the Cybertruck's practical headaches:
<ul>
<li>Nowhere to stand to reach into the cargo bed without slipping on a muddy tire.</li>
<li>A tiny, barely useful "frunk" (front trunk), unlike Ford's spacious, power-outlet-packed Lightning.</li>
<li>$100,000+ price tags for Foundation Series models — while Ford's Lightning is significantly cheaper.</li>
<li>Manufacturing flaws, including body panel gaps so large you could see daylight through them. </li>
</ul>
Even basic controls came under fire. CNN pointed out that while most modern SUVs put the rear camera view inside the rearview mirror — where drivers naturally look — Tesla buried the Cybertruck's rear camera in a small box on the center screen instead. A small thing, but a big clue, the review said, into Tesla's habit of ignoring what people are used to, even when it makes things harder.
"There are indications this attitude contributes to higher crash rates," CNN noted bluntly.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Adding to the challenges, the Cybertruck has been subject to eight recalls since its release in late 2023. Issues have ranged from a faulty accelerator pedal that could become stuck, to windshield wiper failures, and a trunk bed trim that might detach while driving.&nbsp;
The most significant recall affected over 46,000 vehicles due to a stainless steel trim <a href="https://www.nhtsa.gov/">panel that could separate from the vehicle</a>, posing a road hazard. Unlike many Tesla recalls that can be addressed with over-the-air software updates, several of these issues <a href="https://www.tesla.com/support/recall-cybertruck-inverter-replacement">required physical repairs at service centers</a>.
All of this would just be a footnote — if Musk hadn't been so loud a decade ago about how other car companies were the ones wasting money making bad design choices.
Of course, Tesla fans would argue that Musk isn't wrong: the Cybertruck is different <a href="https://www.benzinga.com/startups/24/11/41866041/if-you-want-a-new-tesla-cybertruck-you-can-get-it-built-and-delivered-in-10-days-thats-not-a-good-thing-for-the-ev-company">because it's intentionally radical</a>, a moonshot at reimagining trucks from scratch. But when you've got stainless steel panels that don't line up, small safety features skipped, and a public divided between "visionary" and "eye sore," it's hard not to hear those 2012 words echo back.
Read Next:
<ul>
<li>Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million">invest in RYSE at just $1.90/share.</a></li>
<li><a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a></li>
</ul>
Image: Shutterstock

Elon Musk Was Asked Why Other Car Companies Suck —He Said 'It Blows My Mind' They Choose 'Ugly, Expensive' Designs When 'Good Ones' Cost The Same

Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) has outperformed the market over the past 5 years by 3.51% on an annualized basis producing an average annual return of 17.82%. Currently, Intuit has a market capitalization of $174.44 billion. 
Buying $100 In INTU: If an investor had bought $100 of INTU stock 5 years ago, it would be worth $232.72 today based on a price of $623.98 for INTU at the time of writing.
<h3>Intuit's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746139514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTU

Here's How Much $100 Invested In Intuit 5 Years Ago Would Be Worth Today

Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares are tumbling in Thursday&#8217;s after-hours session on the heels of the company&#8217;s fiscal third-quarter results. Here&#8217;s a look at the highlights <a href="https://www.benzinga.com/pressreleases/25/05/b45149920/atlassian-announces-third-quarter-fiscal-year-2025-results">from the quarter</a>.
Q3 Earnings: Atlassian reported third-quarter revenue of $1.36 billion, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.35 billion. The collaboration and productivity software provider reported third-quarter adjusted earnings of 97 cents per share, beating analyst estimates of 87 cents per share. 
Total revenue climbed 14% year-over-year, driven by Cloud revenue growth of&nbsp;25%&nbsp;year-over-year. 
Atlassian generated $652.7 million in cash flow from operations and $638.3 million in free cash flow during the period. The company ended the quarter with $3 billion of cash, cash equivalents and marketable securities.
&#8220;Our long-term investments in building a world-class Cloud platform have enabled us to advance the Atlassian System of Work and bring Rovo&#8217;s powerful AI capabilities to the center,&#8221; said Mike Cannon-Brookes, co-founder and CEO of Atlassian.
&#8220;Our vision for the future of human-AI collaboration is resonating deeply with customers, and we are more excited than ever to execute on our mission of unleashing the potential of every team.&#8221;
Outlook: Atlassian expects fourth-quarter revenue to be in the range of $1.35 billion to $1.36 billion versus estimates of $1.42 billion. The company anticipates cloud revenue growth of 23% and data center growth of 16.5% on a year-over-year basis in the fourth quarter. Marketplace and other revenue is expected to be approximately flat. 
Atlassian also guided for full-year 2025 revenue of $5.19 billion versus estimates of $5.18 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
TEAM Price Action: <a href="http://benzinga.com/quote/team">Atlassian shares</a> were down 17.71% after-hours, trading at $188.51 at the time of publication on Thursday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45152493/apple-reports-strong-q2-earnings-revenue-beat-eps-beat-installed-base-hits-all-time-high-across-all-segments-100-billion-buyback-and-more">Apple Reports &#8216;Strong&#8217; Q2 Earnings: Revenue Beat, EPS Beat, Installed Base Hits All-Time High Across All Segments, $100 Billion Buyback And More</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/05/45151230/amazon-q1-earnings-double-beat-q2-guidance-ceo-focuses-on-making-customers-lives-easier-and-better">Amazon Q1 Earnings: Double Beat, Q2 Guidance, CEO Focuses On Making &#8216;Customers&#8217; Lives Easier And Better&#8217;</a></li>
</ul>
Photo: Shutterstock.

Earnings

Guidance

After-Hours Center

Movers

TEAM

Atlassian Stock Tanks On Q3 Earnings As Soft Q4 Guidance Overshadows Better-Than-Expected Results

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.18 by 5.56 percent. This is a 13.64 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $34.85 million which beat the analyst consensus estimate of $34.20 million by 1.90 percent. This is a 10.12 percent increase over sales of $31.65 million the same period last year.

Earnings Beats

ASUR

CORRECTION: Asure Software Q1 Adj. EPS $0.19 Beats $0.18 Estimate, Sales $34.85M Beat $34.20M Estimate

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has outperformed the market over the past 10 years by 1.78% on an annualized basis producing an average annual return of 12.16%. Currently, Morgan Stanley has a market capitalization of $187.23 billion. 
Buying $1000 In MS: If an investor had bought $1000 of MS stock 10 years ago, it would be worth $3,117.76 today based on a price of $116.51 for MS at the time of writing.
<h3>Morgan Stanley's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746138611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) sees Q2 sales of $250.000 million-$260.000 million vs $266.61 million analyst estimate.

SNCY

Sun Country Airlines Sees Q2 Sales $250.000M-$260.000M vs $266.61M Est

NPK International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NYSE">NPKI</a>) sees FY2025 sales of $240.000 million-$252.000 million vs $238.13 million analyst estimate.

NPKI

NPK International Sees FY2025 Sales $240.000M-$252.000M vs $238.13M Est

Barclays analyst Jeffrey Bernstein maintains Yum Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) with a Overweight and raises the price target from $163 to $167.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Yum Brands, Raises Price Target to $167

Universal Display (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NASDAQ">OLED</a>) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.07 by 26.17 percent. This is a 13.45 percent increase over earnings of $1.19 per share from the same period last year. The company reported quarterly sales of $166.30 million which beat the analyst consensus estimate of $156.08 million by 6.55 percent. This is a 0.63 percent increase over sales of $165.26 million the same period last year.

OLED

CORRECTION: Universal Display Q1 EPS $1.35 Beats $1.07 Estimate, Sales $166.30M Beat $156.08M Estimate

Barclays analyst Peter Lawson maintains Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Overweight and lowers the price target from $40 to $15.

BCYC

Barclays Maintains Overweight on Bicycle Therapeutics, Lowers Price Target to $15

Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) has outperformed the market over the past 20 years by 9.55% on an annualized basis producing an average annual return of 17.69%. Currently, Equinix has a market capitalization of $83.90 billion. 
Buying $100 In EQIX: If an investor had bought $100 of EQIX stock 20 years ago, it would be worth $2,530.00 today based on a price of $861.97 for EQIX at the time of writing.
<h3>Equinix's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746137714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EQIX

Here's How Much You Would Have Made Owning Equinix Stock In The Last 20 Years

Loop Capital analyst Laura Champine maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Buy and lowers the price target from $25 to $24.

NCLH

Loop Capital Maintains Buy on Norwegian Cruise Line, Lowers Price Target to $24

Loop Capital analyst Gary Mobley maintains Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Hold and lowers the price target from $180 to $155.

QCOM

Loop Capital Maintains Hold on Qualcomm, Lowers Price Target to $155

Loop Capital analyst Laura Champine maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Sell and lowers the price target from $40 to $37.

ETSY

Loop Capital Maintains Sell on Etsy, Lowers Price Target to $37

Maplebear Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) reported first-quarter financial results Thursday after the market close. Shares are moving higher, despite slightly missing analyst estimates. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45149977/instacart-announces-first-quarter-2025-financial-results">of the print.</a>
<ul>
<li>Q1 Revenue: $897 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $898.02 million</li>
</ul>
<ul>
<li>Q1 EPS: 37 cents, versus estimates of 38 cents </li>
</ul>
The delivery aggregator said orders increased 14% year-over-year to 83.2 million in the first quarter as total revenue jumped 9%. Gross transaction value climbed 10% year-over-year to $9.12 billion. 
&#8220;This performance reflects the critical role we play in helping families fill their fridges and pantries, as well as the benefit of our growth initiatives, which are giving consumers even more reasons to turn to Instacart,&#8221; the company said in a letter to shareholders.
See Also: <a href="https://www.benzinga.com/news/earnings/25/05/45152693/roku-q1-double-beat-adds-new-streaming-platform-shares-drop-on-cautious-guidance-tariff-risks">Roku Q1 Double Beat, Adds New Streaming Platform — Shares Drop On Cautious Guidance, Tariff Risks</a>
Guidance: The Instacart parent company guided for a second-quarter gross transaction value of $8.85 billion to $9 billion. The company also anticipates second-quarter Adjusted EBITDA of $240 million to $250 million versus $244 million in the first quarter.
&#8220;Over the past 13 years, we've consistently shown our ability to grow even during periods of macro uncertainty and economic challenges. Groceries aren't discretionary — they're essential — and by helping families save time, money, and effort every day, we're expanding the market, deepening our role in customers' lives, and strengthening our value to our retail and brand partners,&#8221; the company said. 
CART Price Action: <a href="http://benzinga.com/quote/cart">Maplebear shares</a> were up 3.40% after hours, trading at $41.15 at the time of publication on Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock

CART

Instacart Q1 Earnings: Revenue, EPS Come Up Short Despite 14% Order Growth — 'Groceries Aren't Discretionary — They're Essential'

Press Releases

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Offerings

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

LXRX

PRSO

PRTG

RNAZ

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

HCW Biologics

HOOKIPA Pharma

iBio

Imunon

Immuron Limited - American Depositary Shares

Immuron

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

WIIM

TransCode Therapeutics shares are trading higher after the company announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer.

Comments

TransCode Therapeutics

TransCode Therapeutics (RNAZ) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL